Three studies in type 2 diabetes: SERENADE The rimonabant (a blocker of the CB1 receptors) in monotherapy in type 2 diabetes

被引：0
|
作者：
Roussel, R. [1 ]
机构：
[1] CHU Bichat Claude Bernard, Serv Endocrinol Diabetol Nutr, F-75722 Paris 18, France
来源：
ANNALES D ENDOCRINOLOGIE | 2007年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S33 / S35
页数：3
相关论文
共 50 条
  • [21] Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors
    Gelfandt, EV
    Cannon, CP
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (03) : 307 - 315
  • [22] Type 2 Diabetes and ADP Receptor Blocker Therapy
    Samos, Matej
    Fedor, Marian
    Kovar, Frantisek
    Mokan, Michal
    Bolek, Tomas
    Galajda, Peter
    Kubisz, Peter
    Mokan, Marian
    JOURNAL OF DIABETES RESEARCH, 2016, 2016
  • [23] Diabetes in childhood: Type 1, type 2 or "double" diabetes?
    Libman, IM
    Pietropaolo, M
    LaPorte, RE
    Becker, DJ
    PEDIATRIC RESEARCH, 2003, 53 (04) : 130A - 131A
  • [24] Metformin monotherapy for adults with type 2 diabetes mellitus
    Gnesin, Filip
    Thuesen, Anne Cathrine Baun
    Kahler, Lise Katrine Aronsen
    Madsbad, Sten
    Hemmingsen, Bianca
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (06):
  • [25] Rosiglitazone monotherapy is effective in patients with type 2 diabetes
    Lebovitz, HE
    Dole, JF
    Patwardhan, R
    Rappaport, EB
    Freed, MI
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (01): : 280 - 288
  • [26] Computational investigation on the binding modes of Rimonabant analogs with CB1 and CB2
    Liu, Cheng
    Yuan, Congmin
    Wu, Pinwen
    Zhu, Chen
    Fang, Hao
    Wang, Lili
    Fu, Wei
    CHEMICAL BIOLOGY & DRUG DESIGN, 2018, 92 (03) : 1699 - 1707
  • [27] Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes
    Scheen, Andre J.
    Van Gaal, Luc F.
    EUROPEAN HEART JOURNAL, 2007, 28 (11) : 1401 - 1402
  • [28] Diabetic nephropathy in type 1 and type 2 diabetes: Structural studies
    Saller, A
    Dalla Vestra, M
    Bruseghin, M
    Abaterusso, C
    Bortoloso, E
    Velussi, M
    Frigato, F
    Virgili, F
    Baggio, B
    Nosadini, R
    Fioretto, P
    INSULIN RESISTANCE, METABOLIC DISEASES AND DIABETIC COMPLICATIONS, 1999, 1177 : 117 - 127
  • [29] Immunohistochemical distribution of cannabinoid receptor type 1 (CB1) and type 2 (CB2) in the rat carotid body
    Saito, Hiroki
    Yokoyama, Takuya
    Nakamuta, Nobuaki
    Yamamoto, Yoshio
    ACTA HISTOCHEMICA, 2024, 126 (08)
  • [30] α2A-Adrenergic Receptors and Type 2 Diabetes
    Gribble, Fiona M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (04): : 361 - 362
12345